Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open Label, Non-randomised First in Human Study of NG-350A (Monotherapy), and NG-350A With a Check Point Inhibitor in Patients With Metastatic or Advanced Epithelial Tumours

NCT03852511 is registered in ClinicalTrials.gov with Akamis Bio as lead sponsor.

NCT NCT03852511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03852511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open Label, Non-randomised First in Human Study of NG-350A (Monotherapy), and NG-350A With a Check Point Inhibitor in Patients With Metastatic or Advanced Epithelial Tumours
Lead sponsor
Akamis Bio
Phase
Phase 1
Overall status
Completed
Start date
February 19, 2019
Completion date
February 4, 2022
Enrollment
28 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial tumor, metastatic cancer